BridgeMD
Compares treatment options for Postpartum Hemorrhage
Official title Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
ClinicalTrials.gov ID: NCT06285409
What this study is testing
What is Carbetocin?
Carbetocin is an investigational medicine, being studied as a potential treatment for postpartum hemorrhage.
Also referred to as Duratocin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study will investigate the effects of drugs called "uterotonics" that help with the contraction of the uterus after a baby is born. This uterine contraction is very important to stop the bleeding after delivery.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45, women only. Healthy volunteers may be eligible.
You may be able to join if
- Patients who give written consent to participate in this study
- Patients with gestational age 37-41 weeks
- Non-laboring patients, not exposed to exogenous oxytocin
- Patients requiring elective primary or first repeat CD
- Patients undergoing CD under spinal anesthesia
You likely can't join if
- Patient refusal
- Patients who require general anesthesia
- Patients in labour and those receiving oxytocin for induction of labour
- Emergency CD
- placenta accreta spectrum disorder
- Patients who have had previous uterine surgery or \>1 previous CD
See the full eligibility criteria
- Patients who give written consent to participate in this study
- Patients with gestational age 37-41 weeks
- Non-laboring patients, not exposed to exogenous oxytocin
- Patients requiring elective primary or first repeat CD
- Patients undergoing CD under spinal anesthesia
- Patient refusal
- Patients who require general anesthesia
- Patients in labour and those receiving oxytocin for induction of labour
- Emergency CD
- placenta accreta spectrum disorder
- Patients who have had previous uterine surgery or \>1 previous CD
- Patients with any condition predisposing to uterine atony and PPH (BMI \> 40 kg/m2,
- Patients on medications that could affect myometrial contractility, such as insulin, nifedipine, labetalol or magnesium sulphate.
The study team makes the final eligibility decision.
Where it's taking place
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 45 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.